Auris Medical   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Basel Switzerland (2003)
Status: Acquired by Johnson and Johnson (2019)

Organization Overview

First Clinical Trial
2008
NCT00802425
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Auris Health, Inc. | Auris Medical AG | Auris Medical, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

am-111 (3 trials)

esketamine (spravato) (6 trials)

Drugs in Phase 2 Trials (2)

labetalol (trandate) (1 trial)

nifedipine (procardia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Deafness (Phase 3)

Dizziness (Phase 2)

Hearing Loss (Phase 3)

Hearing Loss, Sensorineural (Phase 3)

Neurilemmoma (Phase 2)

Neuroma, Acoustic (Phase 2)

Tinnitus (Phase 3)

Vertigo (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 4